New Antituberculosis Drugs: From Clinical Trial to Programmatic Use

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...

Full description

Saved in:

Bibliographic Details
Published in:	Infectious Disease Reports Vol. 8; no. 2; p. 6569
Main Authors:	Gualano, Gina, CAPONE, Susanna, MATTEELLI, Alberto, Palmieri, Fabrizio
Format:	Journal Article
Language:	English
Published:	Italy MDPI AG 24.06.2016 PAGEPress Publications, Pavia, Italy
Subjects:	antituberculosis therapy Carbapenems Clinical outcomes Clinical trials Conversion Drug resistance Drugs Health services Linezolid Multidrug resistance Multidrug resistant organisms Multidrug-resistant Multidrug-resistant; antituberculosis therapy; new drugs; tuberculosis new drugs Nitroimidazole Other systems of medicine Review RZ201-999 Sputum Tuberculosis Multidrug-resistant antituberculosis therapy new drugs tuberculosis
ISSN:	2036-7449, 2036-7430, 2036-7449
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!